Released Aug 11, 2022, before the open
10-Q filed Aug 11, 2022, 42 days after period end · 0001785530-22-000031
Q2 2022 · 10-Q
Revenue—
Net Income-$14.59M-$14.59M N/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.53-$0.53 N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$14,972,000N/M
Operating Cash Flowderived-$303,000N/M
Free Cash Flowderived-$1,414,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|
| Net Income | -$14.59M | -$10.92M | $2.26M |
| EPS Diluted | -$0.53 | -$3.82 | $0.22 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR